Clinical Research Papers:
Application of embolization microspheres in interventional therapy of malignant non-hypervascular tumor of liver
Metrics: PDF 2243 views | HTML 2667 views | ?
Abstract
Huanzhang Niu1, Tingwei Du1, Quanping Xiao1, Xin Hu1, Dongmin Li1, Chao Wang1, Wanqin Gao1, Taohong Xing1 and Xiangmei Xu1
1 Department of Interventional Radiology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China
Correspondence to:
Huanzhang Niu, email:
Keywords: malignant liver tumors; transarterial embolization; non-hypervascular; microspheres
Received: August 02, 2016 Accepted: March 09, 2017 Published: March 16, 2017
Abstract
Objective: To investigate the efficacy and safety of transarterial embolization (TAE) using embolization microspheres in the treatment of non-hypervascular malignant liver tumors.
Methods: Patients with malignant non-hypervascular liver tumors, who were treated with TAE using embolization microspheres, were selected and analyzed retrospectively. The technical success rate, tumor response, and complications were assessed.
Results: Six patients were included in the study: 1 patient each with hepatocellular-cholangiocarcinoma, intrahepatic cholangiocarcinoma, hepatic metastasis after resection of common bile duct carcinoma, liver metastasis from colon cancer, liver metastasis from esophageal cancer, and liver metastasis from pancreatic cancer. The technical success rate was 100%. At 1 and 3 months after TAE, tumor local reactions were seen in 6/6 and 2/6 patients, respectively, and the tumor necrosis rates were 48%-73% and 22%-68%, respectively. The main complications were those related to the embolization syndrome, including 1 case of liver abscess and 1 case of severe pain on the first day after embolization.
Conclusion: TAE with embolization microspheres is safe and effective in non-hypervascular liver tumors. It is a feasible option for palliative therapy of these tumors.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16286